非清髓异基因造血干细胞移植联合伊马替尼治疗慢性粒细胞白血病的临床研究

被引:1
作者
刘利
刘强
郝淼旺
陈任安
张继良
王黎红
何华
蒋姗姗
梁英民
机构
[1] 第四军医大学唐都医院血液科,第四军医大学唐都医院血液科,第四军医大学唐都医院血液科,第四军医大学唐都医院血液科,第四军医大学唐都医院血液科,第四军医大学唐都医院血液科,第四军医大学唐都医院血液科,第四军医大学唐都医院血液科,第四军医大学唐都医院血液科西安,西安,西安,西安,西安,西安,西安,西安,西安
关键词
造血干细胞移植; 白血病,髓样,慢性; 药物治疗; 伊马替尼; 非清髓;
D O I
暂无
中图分类号
R733.72 [慢性白血病];
学科分类号
100214 ;
摘要
目的 探讨非清髓造血干细胞移植联合伊马替尼(格列卫、STI571)在治疗慢性粒细胞白血病(CML)中的作用。方法 10例CML患者中3例为慢性期,4例为加速期,3例为急变期。移植前、后口服格列卫(400~1500mg/d)治疗,预处理方案为福达拉宾,环磷酰胺和阿糖胞苷联合抗胸腺细胞球蛋白或CD3单抗。供者HLA配型4例完全相合,2例1个位点不相合,1例2个位点不相合的同胞,1例3个位点不相合的同胞及2例半匹配的母亲供者。干细胞来源为重组人类粒细胞集落刺激因子(rhG- CSF,格拉诺赛特)动员的外周血造血干细胞(PBSC),移植物抗宿主病(GVHD)的预防以环孢菌素A和霉酚酸酯(骁悉)为主,部分病例加用甲氨蝶呤、CD3单抗及CD25单抗(塞尼派)。结果 10例患者均获得不同程度的嵌合状态,3例获得完全嵌合(>95%),7例获得44%~95%的混合嵌合。7例混合嵌合状态的患者经调整免疫抑制剂、供者淋巴细胞/PBSC输注,格列卫治疗,6例患者在移植后1 5~10个月转变为完全嵌合。移植后中性粒细胞>0. 5×109/L所需天数为16d(10~21d);血小板大于20×109/L所需天数为10d(4~15d)。移植期间1例患者移植后45d因肠道感染,颅内出血死亡。另1例患者移植后27d因多脏器衰竭死亡。8例患者随访7~23个月,6例发生Ⅰ~Ⅱ度GVHD,2例发生Ⅲ~Ⅳ度GVHD,除1例因慢性GVHD死
引用
收藏
页码:1102 / 1105
页数:4
相关论文
共 11 条
[1]  
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Slavin S,Nagler A,Naparstek E,et al. Blood . 1998
[2]  
Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Champlin R,Khouri I,Shimoni A,et al. British Journal of Haematology . 2000
[3]  
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Wadhwa J,Szydlo RM,Apperley JF,et al. Blood . 2002
[4]  
Imatinib alone and in combination for chronic myeloid leukemia. Druker BJ. Seminars in Hematology . 2003
[5]  
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. A Gratwohl,J Hermans,JM Goldman. The Lancet . 1998
[6]  
Completeremissionfromchronicmyelogenousleukemia———blasticcrisiscausedbyreducedintensitystemcelltransplantationfollowingpartialremissionduetoimatinib. MyojoT,HinoN. International Medical Journal . 2004
[7]  
Secondchronicphasebeforetransplantationiscrucialforimprovingsurvivalofblasticphasechronicmyeloidleukaemia. VisaniG,RostiG,BandiniG, etal. British Journal of Haematology . 2000
[8]  
Allogeneicbonemarrowtransplantationforchronicmyelogenousleukemia: comparativeanalysisofunrelatedversusmatchedsiblingdonortransplantation. WeisdorfDJ,AnasettiC,AntinJ, etal. Blood . 2002
[9]  
Effcacy andsafety of aspecific inhibitor of the BCR-ABLtyrosine kinase in chronic myeloidleukemia. DRUKERBJ,TALPAZ M,RESTA DJ,et al. The New England Journal of Medicine . 2001
[10]   Leukemia [P]. 
英国专利 :GB0221802D0 ,2002-10-30